TY - JOUR T1 - Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease JF - Anticancer Research JO - Anticancer Res SP - 6261 LP - 6266 VL - 35 IS - 11 AU - DAICHI FUJIMOTO AU - RYOKO SHIMIZU AU - RYOJI KATO AU - YUKI SATO AU - MARIKO KOGO AU - JIRO ITO AU - SHUNSUKE TERAOKA AU - TAKEHIRO OTOSHI AU - KAZUMA NAGATA AU - ATSUSHI NAKAGAWA AU - KOJIRO OTSUKA AU - NOBUYUKI KATAKAMI AU - KEISUKE TOMII Y1 - 2015/11/01 UR - http://ar.iiarjournals.org/content/35/11/6261.abstract N2 - Background: The safety and efficacy of second-line chemotherapy for treating patients with small cell lung cancer (SCLC) and interstitial lung disease (ILD) have not been elucidated to date. Patients and Methods: Between January 2005 and September 2013, we analyzed 23 patients with SCLC and ILD who received second-line chemotherapy. Pre-existing ILD was diagnosed according to clinical features and pretreatment chest high-resolution computed tomography results. Results: The overall objective response rates and disease control rates were 22% and 52%, respectively. The median respective durations of progression-free survival and overall survival were 2.1 months (95% confidence interval (CI)=2.0-3.0 months) and 7.1 months (95% CI=3.6-11.3 months), respectively. Three patients with unusual interstitial pneumonia pattern (13%) developed chemotherapy-related pneumonitis. Conclusion: Second-line treatment may be an effective and safe option for SCLC patients with ILD after sufficient evaluation of risks and benefits. ER -